Business Model Breakdown
How Icecure Medical Ltd Makes Money
ICCM
Market Cap
$77M
Profit Margin
0.0%
The Short Version
Icecure Medical develops and commercializes the ProSense cryoablation system, a minimally invasive medical device that uses extreme cold to destroy tumors. The company makes money by selling these systems to hospitals and clinics, primarily for the treatment of small, low-risk breast cancer tumors as a non-surgical alternative. This approach aims to reduce patient recovery time and improve cosmetic outcomes compared to traditional surgery, positioning ProSense as a less invasive option for tumor removal.
Where the Revenue Comes From
Sale of ProSense cryoablation systems and related disposable probes/accessories (~100% of revenue)
Who buys: Hospitals, cancer treatment centers, and surgical clinics, primarily in the U.S. with plans for international expansion.
Why It Works (Competitive Advantages)
- ✔Proprietary cryoablation technology (ProSense) with unique clinical validation for breast cancer (ICE3 trial).
- ✔Regulatory advantage with FDA clearance for low-risk breast cancer and ASBrS guideline inclusion.
- ✔First-mover advantage in non-surgical breast cancer ablation in a largely untapped market.
Economic Moat: Narrow (Intangible Assets/IP (proprietary ProSense technology, patents, clinical data), Switching Costs (for hospitals adopting the technology, training staff, integrating into workflows), Regulatory Advantages (FDA clearance, ASBrS guidelines))
What Our Analysis Says
DVR Score as of April 12, 2026
Icecure Medical shows strong promise with its ProSense cryoablation system, backed by FDA clearance for breast cancer and positive clinical data (ICE3 trial), addressing a large untapped market. This provides a clear competitive advantage and significant long-term growth potential. However, recent financial performance raises substantial concerns. The company reported declining gross margins (44% to 36%), consistent EPS misses, and a significant net loss, implying high cash burn. A major registered direct offering and warrants could lead to over 30% share dilution, significantly impacting shareholder value and making the path to 10x growth more challenging despite clinical advancements. While analyst sentiment is positive, the financial health and capital allocation aspects have materially weakened, tempering the overall high-risk, high-reward potential.